Semi-Annual Consolidated Statement Of Income

BrightPath Biotherapeutics Co., Ltd. - Filing #7331490

Concept	2023-04-01 to 2024-03-31	2023-04-01 to 2024-03-31	2023-04-01 to 2024-03-31	2023-04-01 to 2024-03-31	2022-04-01 to 2023-03-31	2022-04-01 to 2023-03-31	2022-04-01 to 2023-03-31	2022-04-01 to 2023-03-31
Semi-annual consolidated statement of income
Statement of income
Net sales	—	—	72,000 JPY	—	—	5,280,000 JPY	—	—
Cost of sales	—	—	18,000 JPY	—	—	1,895,000 JPY	—	—
Ordinary profit (loss)	—	—	-1,158,929,000 JPY	—	—	-1,473,774,000 JPY	—	—
Gross profit (loss)	—	—	54,000 JPY	—	—	3,384,000 JPY	—	—
Selling, general and administrative expenses
Remuneration for directors (and other officers)	—	—	76,300,000 JPY	—	—	58,300,000 JPY	—	—
Depreciation	—	—	48,000 JPY	—	—	10,000 JPY	—	—
Selling, general and administrative expenses	—	—	1,155,133,000 JPY	—	—	1,470,443,000 JPY	—	—
Extraordinary losses	—	—	7,252,000 JPY	—	—	9,958,000 JPY	—	—
Profit (loss) before income taxes	—	—	-1,166,182,000 JPY	—	—	-1,483,733,000 JPY	—	—
Operating profit (loss)	—	—	-1,155,078,000 JPY	—	—	-1,467,059,000 JPY	—	—
Income taxes - current	—	—	1,900,000 JPY	—	—	1,900,000 JPY	—	—
Non-operating income
Interest income	—	—	12,000 JPY	—	—	20,000 JPY	—	—
Non-operating income	—	—	299,000 JPY	—	—	567,000 JPY	—	—
Non-operating expenses
Non-operating expenses	—	—	4,149,000 JPY	—	—	7,283,000 JPY	—	—
Income taxes	—	—	1,900,000 JPY	—	—	1,900,000 JPY	—	—
Profit (loss)	-1,168,082,000 JPY	-1,168,082,000 JPY	-1,168,082,000 JPY	-1,168,082,000 JPY	-1,485,633,000 JPY	-1,485,633,000 JPY	-1,485,633,000 JPY	-1,485,633,000 JPY
Extraordinary losses
Impairment losses	—	—	7,252,000 JPY	—	—	9,958,000 JPY	—	—